Celularity Inc. (CELU) Bundle
Are you intrigued by companies pushing the boundaries of medicine? Celularity Inc. (CELU) is a clinical-stage biotechnology firm specializing in placental-derived cell therapies and advanced biomaterials, targeting a wide array of diseases from cancer to immune disorders. With $36.1 million in total net revenues reported for the nine months ended September 30, 2024, representing a 238.6% increase compared to the same period last year, and full year 2024 net sales guidance raised to $54 million to $60 million, how does Celularity leverage the unique biology of the placenta to create innovative therapeutic solutions, and what makes their approach stand out in the competitive biotech landscape? Keep reading to discover the history, ownership, mission, operational mechanics, and revenue streams that define Celularity.
Celularity Inc. (CELU) History
Celularity Inc. Founding Timeline
Year established
The company was established in January 2017.
Original location
The company is headquartered in Florham Park, New Jersey.
Founding team members
While specific founding team members are not explicitly detailed in the provided search results, it is known that Robert Hariri, MD, PhD, is a key figure. He is the Founder, Chairman, and Chief Executive Officer.
Initial capital/funding
Information on the specific initial capital or funding at the company's founding in 2017 is not available in the provided search results.
Celularity Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2017 | Company Established | Marks the beginning of the company focusing on cellular medicine. |
| 2021 | Merger with GX Acquisition Corp | Became a publicly listed company on the Nasdaq, ticker symbol: CELU. This merger provided capital to advance clinical programs. |
| 2022 | Partnership with Immatics | Collaboration to develop allogeneic cell therapies using Immatics' target discovery platform, XPRESIDENT®. |
| 2023 | FDA Clearance of PMA Supplement for Intervertebral Body Fusion Device | The FDA cleared a PMA supplement for the company’s intervertebral body fusion device containing viable cells, expanding its market reach. |
Celularity Inc. Transformative Moments
- Merger with GX Acquisition Corp (2021): This was a pivotal moment, providing the company with the necessary capital to become a publicly traded entity and further advance its clinical trials and research initiatives.
- Strategic Partnerships: Collaborations, such as the one with Immatics, have been crucial in expanding the company's technological capabilities and therapeutic pipeline in allogeneic cell therapies.
- FDA Clearances: Regulatory milestones, including FDA clearance for its intervertebral body fusion device, validate the company's technology and open new avenues for commercialization.
- Focus on Placental-Derived Cells: The company's unique focus on using postpartum human placental cells and biomaterials has set it apart in the field of regenerative medicine, offering novel approaches to treating diseases.
To gain more insights into the company's guiding principles, you might find this resource helpful: Mission Statement, Vision, & Core Values of Celularity Inc. (CELU).
Celularity Inc. (CELU) Ownership Structure
Celularity Inc.'s ownership is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders. Understanding this structure provides insights into the company's governance and strategic direction.
Celularity's Current Status
Celularity Inc. is a publicly traded company, meaning its shares are available for purchase on the open market. This allows a wide range of investors to own a portion of the company. For more in-depth insights into Celularity's investor profile, you can explore: Exploring Celularity Inc. (CELU) Investor Profile: Who’s Buying and Why?
Celularity's Ownership Breakdown
The following table provides an overview of Celularity's ownership structure based on the latest available data. Please note that ownership percentages can fluctuate due to ongoing trading activities.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 57.48% | Includes investment firms, mutual funds, and other institutions. |
| Individual Insiders | 2.18% | Shares held by officers and directors. |
| General Public | 40.34% | Shares held by retail investors. |
Celularity's Leadership
Celularity's direction is guided by a team of experienced leaders. Here are some of the key figures:
- Robert J. Hariri, M.D., Ph.D.: Founder, Chairman, and Chief Executive Officer
- Adrian Kilcoyne, M.D., Ph.D.: Executive Vice President, Chief Medical Officer
- Paul Hering: Chief Financial Officer
These individuals, along with other members of the executive team and board of directors, are responsible for setting the strategic course of Celularity and overseeing its operations. Their leadership is crucial in driving the company's mission and achieving its financial goals.
Celularity Inc. (CELU) Mission and Values
Celularity's mission is centered on harnessing the power of allogeneic cellular medicine to develop innovative treatments for cancer and immune and age-related diseases. The company is dedicated to extending and improving human health through its advanced technology platforms and therapeutic programs.
Celularity Inc.'s Core Purpose
Official mission statement
Celularity's mission statement is: 'To lead the next evolution in cellular medicine by developing and delivering innovative allogeneic cell therapies that unlock the potential of the human body to treat disease and extend healthy human lifespan.'
- Focuses on advancing the field of cellular medicine.
- Aims to create therapies that utilize the body's own capabilities to fight diseases.
- Strives to increase the duration of a healthy life.
Vision statement
Celularity envisions 'a future where cellular medicine transforms the treatment of cancer, immune disorders, and age-related diseases, providing patients with access to innovative therapies that offer hope for a longer and healthier life.'
- Seeks to revolutionize treatment approaches for major health challenges.
- Aims to make advanced cellular therapies widely accessible.
- Aspires to significantly improve patient outcomes and quality of life.
Company slogan/tagline
Celularity's tagline, 'Unlocking the Power of Cellular Medicine,' encapsulates its commitment to pioneering breakthroughs in cell therapy and regenerative medicine.
- Highlights the company's focus on cellular medicine.
- Emphasizes innovation and discovery in their therapeutic development.
- Communicates the potential of their therapies to transform healthcare.
To delve deeper into Celularity's mission, vision, and core values, you can visit: Mission Statement, Vision, & Core Values of Celularity Inc. (CELU).
Celularity Inc. (CELU) How It Works
Celularity Inc. operates as a clinical-stage biotechnology company focused on developing cellular medicines and biomaterial products. They harness the unique properties of the postpartum human placenta to address unmet medical needs across cancer, infectious diseases, and degenerative diseases.
Celularity Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| CYNK-001 | Adults with relapsed or refractory multiple myeloma (MM), and for the treatment of acute myeloid leukemia (AML). | Off-the-shelf, allogeneic natural killer (NK) cell therapy derived from placental hematopoietic stem cells; designed to enhance immune response against cancer cells. |
| CYNK-101 | solid tumors | Genetically modified NK cell therapy expressing a high-affinity, non-cleavable CD38 targeting receptor. |
| PDA-002 | Degenerative Disc Disease | Human placental derived cells to target degenerative disc disease |
Celularity Inc.'s Operational Framework
Celularity's operational framework is built around leveraging its proprietary IMPACT™ platform, which is designed to efficiently source, expand, and cryopreserve placental-derived cells. The company focuses on:
- Cell Sourcing and Manufacturing: Utilizing postpartum placentas obtained from healthy, consenting donors. Celularity has developed processes to isolate and expand various cell types, including NK cells and mesenchymal stem cells.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of its cell therapies and biomaterial products. This involves preclinical studies, Phase 1, Phase 2, and potentially Phase 3 trials to gain regulatory approvals.
- Partnerships and Collaborations: Collaborating with other biotechnology and pharmaceutical companies, as well as academic institutions, to advance its research and development efforts.
- Intellectual Property: Building a strong intellectual property portfolio around its cell therapy technologies and manufacturing processes.
More insights about Celularity Inc.'s financial standings can be found here: Breaking Down Celularity Inc. (CELU) Financial Health: Key Insights for Investors
Celularity Inc.'s Strategic Advantages
- Placental Cell Source: Utilizing the postpartum placenta as a source of cells provides a unique advantage, as it is an abundant and ethically sourced material.
- Proprietary Technology Platform: The IMPACT™ platform enables efficient cell sourcing, expansion, and cryopreservation, providing a competitive edge in manufacturing and scalability.
- Diverse Product Pipeline: Celularity's pipeline includes cell therapies and biomaterial products targeting a wide range of diseases, reducing the risk associated with relying on a single product.
- Strategic Partnerships: Collaborations with leading institutions and companies enhance Celularity's research and development capabilities and market reach.
Celularity Inc. (CELU) How It Makes Money
Celularity Inc. primarily generates revenue through the development and commercialization of cellular medicines, biomaterials, and related services, focusing on placental-derived allogeneic cell therapies and advanced technologies.
Celularity Inc.'s Revenue Breakdown
As of fiscal year 2024, Celularity's revenue streams can be broken down as follows:
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Product Sales (Cellular Medicines & Biomaterials) | Approximately 65% | Increasing |
| Licensing and Royalties | Approximately 25% | Stable |
| Contract Manufacturing and Services | Approximately 10% | Decreasing |
Celularity Inc.'s Business Economics
Celularity operates with a focus on innovative technologies and therapies derived from placental stem cells. Its economic model is influenced by several key factors:
- R&D Investment: A significant portion of Celularity's expenditure is allocated to research and development, essential for creating new products and enhancing existing technologies.
- Clinical Trial Costs: Advancing therapeutic candidates through clinical trials represents a substantial investment, with costs varying based on trial phase and complexity.
- Manufacturing Costs: The production of cellular medicines and biomaterials involves specialized facilities and processes, impacting the cost of goods sold.
- Partnerships and Collaborations: Strategic alliances can provide Celularity with additional funding, resources, and market access, affecting overall profitability.
- Regulatory Environment: Navigating regulatory approvals, particularly from bodies like the FDA, influences both the timeline and cost of bringing products to market.
Celularity Inc.'s Financial Performance
Celularity's financial performance can be assessed through the following metrics:
- Revenue Growth: Monitoring the year-over-year growth in product sales, licensing revenue, and service income indicates the company's market penetration and acceptance.
- Gross Margin: Analyzing the gross margin helps evaluate the efficiency of Celularity's production processes and pricing strategies.
- Operating Expenses: Tracking operating expenses, including R&D and SG&A, provides insights into the company's cost management and investment in future growth.
- Cash Flow: Evaluating cash flow from operations, investing, and financing activities is crucial for assessing Celularity's liquidity and financial stability.
- Net Loss: Celularity, like many biotech companies, may experience net losses as it invests heavily in R&D. The trend and magnitude of these losses are important for investors to monitor.
For more detailed insights into Celularity's financial health, you can explore: Breaking Down Celularity Inc. (CELU) Financial Health: Key Insights for Investors
Celularity Inc. (CELU) Market Position & Future Outlook
Celularity Inc. is navigating a challenging but potentially transformative period, focusing on leveraging its placental-derived cell therapy platform to address unmet needs in immuno-oncology and degenerative diseases. The company's future hinges on successful clinical trial outcomes, strategic partnerships, and effective commercialization strategies within a competitive biotechnology landscape.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Celularity Inc. | ~1-2% (estimated, niche market) | Proprietary placental-derived cell therapy platform |
| Novartis | ~20% (oncology) | Established CAR-T therapy, global reach |
| Gilead Sciences | ~18% (oncology) | Strong oncology portfolio, CAR-T expertise |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancing clinical trials of lead candidates CYNK-001 and CYNK-101 in hematologic cancers and solid tumors. | Clinical trial failures or delays impacting pipeline progress. |
| Expanding strategic partnerships to broaden development and commercialization reach. | Regulatory hurdles and evolving approval landscape for cell therapies. |
| Leveraging proprietary cell therapy platform for new therapeutic applications and indications. | Intense competition from established pharmaceutical companies and emerging biotech firms. |
Industry Position
Celularity operates within the dynamic and competitive cell therapy and regenerative medicine sectors. Here are key aspects of its industry positioning:
- Niche Player: Celularity focuses on placental-derived cell therapies, differentiating itself from companies with broader technology platforms.
- Clinical-Stage Focus: As of April 2025, Celularity is primarily a clinical-stage company, with its value heavily tied to the success of its ongoing clinical trials.
- Partnerships: Strategic alliances are crucial for Celularity to access resources, expertise, and market access that complement its internal capabilities.
- More insights about Celularity Inc. are available here: Mission Statement, Vision, & Core Values of Celularity Inc. (CELU).
Celularity Inc. (CELU) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.